HCW Biologics Inc.
13F holders, Q1 2025 (March 31)15holders −3
4new positions
7sold out
$0.28avg. 13F price*
At the end of Q1 2025, 15 institutions reported holding HCW Biologics Inc. in their 13F filings, down 3 from Q4 2024. 4 opened new positions and 7 sold out. The largest holders were Avantax Planning Partners, Inc. ($79K), Vanguard Group Inc. ($69K) and Geode Capital Management, LLC ($67K).
- Company
- HCW Biologics Inc.
- CUSIP
- 40423R105
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $24K |
| Exits | 7 | $1.0M |
All 13F filers, Q4 2024 → Q1 2025: 345,278 shares bought and 2,318,440 shares sold, net −1,973,162 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Avantax Planning Partners, Inc. | 0.00% | No change | 279,541 | $79K |
| Vanguard Group Inc. | 0.00% | Add +545.4% | 243,158 | $69K |
| Geode Capital Management, LLC | 0.00% | Add +30.2% | 236,967 | $67K |
| Cresset Asset Management, LLC | 0.00% | No change | 131,990 | $37K |
| Pullen Investment Management, LLC | 0.01% | No change | 75,116 | $21K |
| J.W. Cole Advisors, Inc. | 0.00% | New | 53,402 | $15K |
| BlackRock, Inc. | 0.00% | Reduce -1.9% | 42,182 | $12K |
| AE Wealth Management LLC | 0.00% | No change | 30,000 | $8K |
| State Street Corp. | 0.00% | No change | 21,446 | $6K |
| Vanguard Personalized Indexing Management, LLC | 0.00% | New | 16,264 | $5K |
| Citigroup Inc. | 0.00% | New | 14,047 | $4K |
| Northern Trust Corp. | 0.00% | No change | 10,205 | $3K |
| Osaic Holdings, Inc. | 0.00% | New | 1,010 | $285 |
| Bank of America Corp. | 0.00% | Add +43.8% | 210 | $59 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -98.2% | 32 | $9 |
"% of holder's portfolio" is HCW BIOLOGICS INC's weight in each manager's 13F, not the share of HCW Biologics Inc. the manager owns.